Meeting
2023 ASCO Annual Meeting
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
Authors
Lorenzo Gerratana
CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy
Lorenzo Gerratana , Yue Ren , Carolina Reduzzi , Meredith M. Regan , Reshma L. Mahtani , Cynthia X. Ma , Angela DeMichele , Jane Lowe Meisel , Kathy Miller , Trevor Augustus Jolly , Elizabeth Carloss Riley , Rubina Qamar , Priyanka Sharma , Sonya A. Reid , Naomi Yu Ko , Yuan Liu , Harold J. Burstein , Sara M. Tolaney , Massimo Cristofanilli , Erica L. Mayer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03147287
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1059)
DOI
10.1200/JCO.2023.41.16_suppl.1059
Abstract #
1059
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.
First Author: Erica L. Mayer
Poster
2023 ASCO Annual Meeting
Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
First Author: Alicia Frances Clare Okines
Poster
2017 ASCO Annual Meeting
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
First Author: Kevin Kalinsky
Poster
2022 ASCO Annual Meeting
Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER⁺) breast cancer or advanced solid tumors.
First Author: Kevin Kalinsky